CTX vs. HEXO, VIR, LABS, ZOM, META, DB, VM, NRTH, MRV, and CWEB
Should you be buying Crescita Therapeutics stock or one of its competitors? The main competitors of Crescita Therapeutics include HEXO (HEXO), Viridium Pacific Group (VIR), MediPharm Labs (LABS), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Meta Growth (META), Decibel Cannabis (DB), Voyageur Pharmaceuticals (VM), 48North Cannabis (NRTH), Nuvo Pharmaceuticals (MRV), and Charlotte's Web (CWEB). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Crescita Therapeutics vs.
HEXO (TSE:HEXO) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Crescita Therapeutics has a net margin of -15.73% compared to HEXO's net margin of -220.13%. Crescita Therapeutics' return on equity of -15.60% beat HEXO's return on equity.
In the previous week, HEXO's average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.
Crescita Therapeutics has lower revenue, but higher earnings than HEXO. Crescita Therapeutics is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.
7.6% of HEXO shares are owned by institutional investors. 3.0% of HEXO shares are owned by company insiders. Comparatively, 10.9% of Crescita Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Crescita Therapeutics received 3 more outperform votes than HEXO when rated by MarketBeat users. Likewise, 67.42% of users gave Crescita Therapeutics an outperform vote while only 47.90% of users gave HEXO an outperform vote.
HEXO has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Crescita Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.
Summary
Crescita Therapeutics beats HEXO on 8 of the 12 factors compared between the two stocks.
Get Crescita Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crescita Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CTX) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy CTX Stock Free CTX Stock Alerts